In adult patients with CKD associated with T2DHyperkalemia was the most commonly reported adverse reaction in patients taking KERENDIA1
Initiation of KERENDIA may cause an initial small decrease in estimated GFR that occurs within the first 4 weeks of starting therapy, and then stabilizes. In a study that included patients with CKD associated with T2D, this decrease was reversible after treatment discontinuation.1
CKD=chronic kidney disease; GFR=glomerular filtration rate; T2D=type 2 diabetes.
eGFR=estimated glomerular filtration rate.